4 research outputs found
Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells
Pancreatic
ductal adenocarcinoma (PDAC) is an aggressive disease
with poor prognosis and limited therapeutic options. Therefore, there
is an urgent need to identify new, safe, and targeted therapeutics
for effective treatment of late as well as early stage disease. Plectin-1
(Plec-1) was recently identified as specific biomarker for detecting
PDAC at an early stage. We envisioned that multivalent attachment
of nanocarriers incorporating certain drugs to Plec-1-derived peptide
would increase specific binding affinity and impart high specificity
for PDAC cells. Previously, we discovered a novel class of compounds
(e.g., quinazolinediones, QDs) that exert their cytotoxic effects
by modulating ROS-mediated cell signaling. Herein, we prepared novel
QD242-encapsulated polymeric nanoparticles (NPs) functionalized with
a peptide to selectively bind to Plec-1. Similarly, we prepared QD-based
NPs densely decorated with an isatoic anhydride derivative. Furthermore,
we evaluated their impact on ligand binding and antiproliferative
activity against PDAC cells. The targeted NPs were more potent than
the nontargeted constructs in PDAC cells warranting further development
Carbonic Anhydrase Inhibition with Benzenesulfonamides and Tetrafluorobenzenesulfonamides Obtained via Click Chemistry
A series
of novel benzene- and 2,3,5,6-tetrafluorobenzenesulfonamide was synthesized
by using a click chemistry approach starting from azido-substituted
sulfonamides and alkynes, incorporating aryl, alkyl, cycloalkyl, and
amino-/hydroxy-/halogenoalkyl moieties. The new compounds were medium
potency inhibitors of the cytosolic carbonic anhydrase (CA, EC 4.2.1.1)
isoforms I and II and low nanomolar/subnanomolar inhibitors of the
tumor-associated hCA IX and XII isoforms. The X-ray crystal structure
of two such sulfonamides in adduct with hCA II allowed us to understand
the factors governing inhibitory power
Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors
The influenza virus RNA-dependent
RNA polymerase complex (RdRp),
a heterotrimeric protein complex responsible for viral RNA transcription
and replication, represents a primary target for antiviral drug development.
One particularly attractive approach is interference with the endonucleolytic
“cap-snatching” reaction by the RdRp subunit PA, more
precisely by inhibiting its metal-dependent catalytic activity which
resides in the N-terminal part of PA (PA-Nter). Almost all PA inhibitors
(PAIs) thus far discovered bear pharmacophoric fragments with chelating
motifs able to bind the bivalent metal ions in the catalytic core
of PA-Nter. More recently, the availability of crystallographic structures
of PA-Nter has enabled rational design of original PAIs with improved
binding properties and antiviral potency. We here present a coupled
pharmacophore/docking virtual screening approach that allowed us to
identify PAIs with interesting inhibitory activity in a PA-Nter enzymatic
assay. Moreover, antiviral activity in the low micromolar range was
observed in cell-based influenza virus assays
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors
We report the synthesis,
biological evaluation, and structural
study of a series of substituted heteroaryl-pyrazole carboxylic acid
derivatives. These compounds have been developed as inhibitors of
specific isoforms of carbonic anhydrase (CA), with potential as prototypes
of a new class of chemotherapeutics. Both X-ray crystallography and
computational modeling provide insights into the CA inhibition mechanism.
Results indicate that this chemotype produces an indirect interference
with the zinc ion, thus behaving differently from other related nonclassical
inhibitors. Among the tested compounds, <b>2c</b> with <i>K</i><sub>i</sub> = 0.21 μM toward <i>h</i>CA
XII demonstrated significant antiproliferative activity against hypoxic
tumor cell lines. Taken together, the results thus provide the basis
of structural determinants for the development of novel anticancer
agents